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Androgen deprivation therapy (ADT) increases fracture risk in men with carcinoma of the
prostate, but little is known about the fracture risk for different types of ADT. We studied the
fracture risk amongst Chinese patients with carcinoma of the prostate prescribed different
ADT regimens.
Subjects and methods
This was a single-centered observational study that involved 741 patients with carcinoma of
the prostate from January 2001 to December 2011.
Results
After a median follow-up of 5 years, 71.7% of the study cohort received ADT and the inci-
dence rate of fracture was 8.1%. Multivariable Cox regression analysis revealed that use of
ADT was significantly associated with risk of incident fracture (Hazard Ratio [HR] 3.60; 95%
Confidence Interval [95% CI] 1.41–9.23; p = 0.008), together with aged >75 years and type
2 diabetes. Compared with no ADT, all three types of ADT were independently associated
with the risk of incident fracture: anti-androgen monotherapy (HR 4.47; 95% CI 1.47–13.7;
p = 0.009), bilateral orchiectomy ± anti-androgens (HR 4.01; 95% CI 1.46–11.1; p = 0.007)
and luteinizing hormone-releasing hormone agonists ± anti-androgens (HR 3.16; 95% CI
1.18–8.43; p = 0.022). However, there was no significant difference in the relative risks
among the three types of ADT.
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Conclusions
Fracture risk increases among all types of ADT. Clinicians should take into account the risk-
benefit ratio when prescribing ADT, especially in elderly patients with type 2 diabetes.
Introduction
Carcinoma of the prostate, a classic hormone-dependent malignancy, is the second most fre-
quent cancer diagnosed and is the sixth most common cause of death in men worldwide.[1,2]
In Hong Kong, carcinoma of the prostate ranks as the third leading cancer in men, accounting
for 6.5% of all cancers in those aged 45–64 years and 17% in those aged 65–74 years.[3] Over
the last decade, the incidence of prostate carcinoma has been steadily increasing by 4.6% per
annum, probably related to the aging population as well as a more westernized lifestyle in
Hong Kong.[4]
Because it is androgen dependent, androgen deprivation therapy (ADT) is the mainstay sys-
temic treatment in patients with metastatic carcinoma of the prostate.[5] It has also been
widely used amongst those with less advanced disease.[6,7] To date, androgen deprivation can
be achieved in several ways: surgically by performing bilateral orchiectomy, or pharmacologi-
cally with gonadotrophin-releasing hormone (GnRH) agonists such as luteinizing hormone-
releasing hormone agonists (LHRHa), GnRH antagonists, and non-steroidal anti-androgen
drugs such as bicalutamide and flutamide. Since many patients with carcinoma of the prostate
often have a favorable prognosis and not uncommonly live a near-normal lifespan, the benefits
of any treatment that aims to further improve long-term outcome should outweigh any poten-
tial treatment-associated adverse effects. The metabolic effects as well as the cardiovascular
consequences of ADT have been increasingly recognized.[8] More recently, clinical data have
suggested a higher fracture risk amongst patients with carcinoma of the prostate prescribed
ADT.[9] This can lead to impaired quality of life [10] and/or even mortality.[11] Nonetheless
previous studies that demonstrated ADT-associated fracture risks often focused on an individ-
ual type of ADT such as bilateral orchiectomy [12], or LHRH agonists [13], [14], or considered
several types of ADT as a whole.[15] Given the different mechanisms of achieving androgen
deprivation, it is conceivable that different types of ADT might confer a differential risk of
fracture. The aim of this study was to evaluate the fracture risk for different forms of ADT [16]
using data from a retrospective cohort of Chinese patients with carcinoma of the prostate.
Methods
Patients
Patients with a diagnosis of carcinoma of the prostate who were followed up at Queen Mary
Hospital, Hong Kong between January 2001 and December 2011, were identified through the
computer-based clinical management system. Patients were excluded if they had previously
documented osteoporosis and/or fracture(s) at the time of diagnosis of prostate carcinoma.
Patients were then classified according to the type of ADT: (1) No ADT, (2) Bilateral orchiec-
tomy with or without anti-androgens, (3) LHRHa with or without anti-androgens, or (4) Anti-
androgen monotherapy such as cyproterone, flutamide, bicalutamide and ketoconazole. Those
who were prescribed LHRHa or anti-androgen monotherapy had to have received at least 6
months of treatment to be included in this study. The final analysis included 741 patients with
carcinoma of the prostate.
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Design
This was a single-centered, observational study conducted at a university hospital in Hong
Kong. The study was approved by the Institutional Review Board of the University of Hong
Kong / Hospital Authority Hong Kong West Cluster. Given the registry nature of the study,
informed consent was not obtained from patients; nonetheless all patient records and informa-
tion were rendered anonymous prior to analysis. Clinical data pertaining to fracture risk
including demographics (age and smoking), medical history (co-morbidities including diabe-
tes mellitus, hypertension, hypercholesterolemia, coronary artery disease, and stroke) and
drug history (use of anti-osteoporotic medications, calcium or vitamin D supplements) were
recorded at baseline.
Outcomes, variables and data source
The primary outcome was hospital admission for fracture. An incident fracture was defined as
the first recorded diagnosis of fracture verified from the Hospital Authority database as of 31st
December 2014. Diagnoses of fracture were based on International Classification of Diseases
ninth version (ICD-9) (733, 805–809, 810–819 and 820–829). All medical records were reviewed
and the endpoints were adjudicated such that traumatic or pathological fractures, which were
based on bone scan or histology, were excluded. Data were retrieved from the medical records
and discharge summaries of the territory-wide information network of all public hospitals in
Hong Kong.
Statistical analyses
Data that were not normally distributed, as determined using Kolmogorov-Smirnov test, were
natural-logarithmically transformed to obtain near normality before analysis. Values are reported
as mean ± standard deviation (SD) or median with inter-quartile range (IQR) as appropriate.
Chi-square test and ANOVA were used for comparison of categorical and continuous variables,
respectively. Multivariable Cox regression analysis was used to estimate the hazard ratio (HR)
and 95% confidence interval (CI) for incident fractures. The variables included in Cox regression
models were those that were statistically significant in univariate analysis. In all statistical tests,
two-sided p-value<0.05 was considered significant. All analyses were performed with IBM SPSS
Statistics 19.
Results
A total of 741 subjects with carcinoma of the prostate were recruited. The mean age was 72.9
±8.5 years. Table 1 summarizes their baseline clinical characteristics: 375 patients (50.6%) had
hypertension; 125 patients (16.9%) had diabetes mellitus; 73 patients (9.9%) had coronary
artery disease; and 41 (5.5%) had stroke. Amongst these, 210 patients (28.3%) had not received
any ADT, and the remaining 530 patients (71.7%) were prescribed various types of ADT. Bilat-
eral orchiectomy had been performed in 225 patients (30.4%) with or without non-steroidal
anti-androgen drugs; 245 patients (33.1%) had LHRHa with or without non-steroidal anti-
androgen drugs; and 61 (8.2%) were prescribed non-steroidal anti-androgen drugs only.
After a median follow-up of 5 years, 60 patients had an incident fracture (8.1%). Patients
with incident fracture were older compared with patients without incident fracture (76.8±8.1
years, vs. 72.6±8.5 years, p<0.001), but there were no other statistically significant differences
in terms of their smoking status, co-morbid medical conditions, or use of steroids during the
follow-up period. Nonetheless patients with incident fracture were more likely to be prescribed
ADT compared with those without fracture (91.7% vs. 69.9%, p = 0.002). It is noteworthy that
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of these 60 incident fractures, 55 occurred in patients prescribed ADT (10.3%), and only 5
occurred in patients not on ADT (2.4%). The annual incidence of fracture was 19.8 per 10,000
persons-years amongst patients on ADT compared with only 3.98 per 10,000 persons-years
amongst those not on ADT. On multivariable Cox regression analysis, only age older than 75
years (HR: 2.93; 95% CI: 1.01–8.44; p = 0.046), presence of diabetes mellitus (HR: 1.83; 95%
CI: 1.01–3.37; p = 0.045) and use of ADT (HR 3.60; 95% CI: 1.41–9.23; p = 0.008) were associ-
ated with increased risk of incident fracture. (Table 2) In addition, compared with no ADT, all
three types of ADT were independently associated with an increased risk of incident fracture:
anti-androgen monotherapy (HR: 4.47; 95% CI: 1.47–13.7; p = 0.009), bilateral orchiectomy ±
anti-androgens (HR: 4.01; 95% CI: 1.46–11.1; p = 0.007), and LHRHa ± anti-androgens (HR:
3.16; 95% CI: 1.18–8.43; p = 0.022). However, there was no significant difference in the relative
risks among the three types of ADT (Bilateral orchiectomy ± anti-androgens vs. LHRHa ± anti-
androgens, p = 0.994; bilateral orchiectomy ± anti-androgens vs. anti-androgens alone, p = 0.202;
LHRHa ± anti-androgens vs. anti-androgens monotherapy, p = 0.200). Fig 1 depicts the Kaplan
Meier analysis of incident fracture amongst patients with carcinoma of the prostate prescribed
different ADT regimens (log rank: 17.327, p<0.001). The results were similar after excluding
those patients prescribed LHRHa alone and those who had bilateral orchiectomy without anti-
androgens. Amongst those with bilateral orchiectomy or LHRHa, the addition of anti-androgen
monotherapy did not increase the risk of incident fracture (bilateral orchiectomy HR: 1.30; 95%
CI: 0.72–2.33; p = 0.383; and LHRHa HR: 1.36; 95% CI: 0.32–5.76; p = 0.676).
Discussion
We compared the incidence rate of fracture in a contemporary cohort of patients with carci-
noma of the prostate in regard to their ADT regimen. Our results identified several risk factors
for incident fracture in this cohort of Chinese patients with carcinoma of the prostate, includ-
ing aged more than 75 years, type 2 diabetes, and the use of ADT. Furthermore, all three forms
Table 1. Baseline characteristics of patients.
Baseline variables Incident fracture
All (N = 741) Yes (N = 60) No (N = 681) p-value
Age (years) 72.9±8.5 76.8±8.1 72.6±8.5 <0.001
Current smoker, n (%) 292 (39.4) 30 (50.0) 262 (38.5) 0.080
Diabetes mellitus, n (%) 125 (16.9) 15 (25.0) 110 (16.2) 0.079
Hypertension, n (%) 375 (50.6) 32 (53.3) 343 (50.4) 0.660
Hypercholesterolemia, n (%) 126 (17.0) 5 (8.3) 121 (17.8) 0.062
Coronary artery disease, n (%) 73 (9.9) 6 (10.0) 67 (9.8) 0.968
Stroke, n (%) 41 (5.5) 6 (10.0) 35 (5.1) 0.114
Use of steroid, n (%) 34 (4.6) 2 (3.3) 32 (4.7) 0.631
Use of calcium or vitamin D supplements, n (%) 116 (15.7) 8 (13.3) 108 (15.9) 0.713
Use of anti-osteoporotic medications, n (%) 56 (7.6) 1 (1.7) 55 (8.1) 0.076
Types of ADT 0.002
None, n (%) 210 (28.3) 5 (8.3) 205 (30.1)
Orchiectomy ± anti-androgens, n (%) 225 (30.4) 22 (36.7) 203 (29.8)
LHRHa ± anti-androgens, n (%) 245 (33.1) 24 (40.0) 221 (32.5)
Anti-androgens alone, n (%) 61 (8.2) 9 (15.0) 52 (7.6)
ADT, Androgen deprivation therapy; LHRHa, Luteinizing hormone releasing hormone agonists.
doi:10.1371/journal.pone.0171495.t001
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Table 2. Association of baseline factors with incident fracture.
Baseline variables Number of fractures Univariate analysis Multivariable Stepwise Cox
regression
HR (95% CI) p-value HR (95% CI) p-value
Age at diagnosis 0.001** 0.038*
<65 4 Reference Reference
65–75 20 2.04 (0.70–5.97) 0.194 1.63 (0.55–4.82) 0.374
>75 36 4.45 (1.58–12.5) 0.005** 2.93 (1.01–8.44) 0.046*
Current smoker 30 1.73 (1.05–2.88) 0.033*
Diabetes mellitus 15 1.95 (1.09–3.51) 0.025* 1.83 (1.01–3.37) 0.045*
Hypertension 32 1.20 (0.72–1.99) 0.485
Hypercholesterolemia 5 0.45 (0.18–1.13) 0.090
Coronary artery disease 6 1.11 (0.48–2.57) 0.815
Stroke 6 2.37 (1.02–5.50) 0.045*
Use of steroid 2 0.84 (0.20–3.43) 0.805
Use of calcium or vitamin D supplements 8 0.86 (0.41–1.80) 0.683
Use of anti-osteoporotic medications 1 0.33 (0.05–2.37) 0.269
Use of ADT 55 5.01 (2.00–12.5) 0.001**
Type of ADT 0.003** 0.041*
None 5 Reference Reference
Orchiectomy ± anti-androgens 22 6.09 (2.30–16.1) <0.001*** 4.01 (1.46–11.1) 0.007**
LHRHa ± anti-androgens 24 4.13 (1.57–10.8) 0.004** 3.16 (1.18–8.43) 0.022*
Anti-androgens alone 9 5.79 (1.93–17.4) 0.002** 4.47 (1.47–13.7) 0.009**
*p<0.05
**p<0.01
***p<0.001; Bilateral orchiectomy ± anti-androgens vs. LHRHa ± anti-androgens, p = 0.994; bilateral orchiectomy ± anti-androgens vs. anti-androgens
alone, p = 0.202; LHRHa ± anti-androgens vs. anti-androgens monotherapy, p = 0.200); HR (95% CI), hazard ratios; ADT, Androgen deprivation therapy;
LHRHa, Luteinizing hormone releasing hormone agonists. Multivariable Cox regression included all variables with p <0.05 in univariate analysis.
doi:10.1371/journal.pone.0171495.t002
Fig 1. Kaplan Meier analysis of fracture-free survival among patients prescribed various types of
ADT.
doi:10.1371/journal.pone.0171495.g001
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of most commonly used ADT regimens were associated with significant increased risk of inci-
dent fracture, although there was no significant difference in the relative risks among them.
As is well known, patients with osteoporotic fractures suffer from significant morbidity and
mortality. Up to 20% of patients with hip or vertebral fractures die within 5 years of the event,
and the mortality rate is highest in men aged over 75 years with multiple co-morbid condi-
tions. Moreover, among those who suffer hip fracture, 40% are reportedly unable to walk inde-
pendently one year after the event, 60% require assistance in at least one essential activity of
daily living, and 80% have difficulty with at least one instrumental activity of daily living.[17]
Since about 75% of prostate cancers occur in elderly men aged 65 years or older, most are
already at increased risk of osteoporotic fractures on the basis of age alone.[18] The use of
ADT further accelerates this age-related bone loss with resultant clinical fractures.[18]
Although the incidence of fracture worldwide increases progressively with age, the inci-
dence rate nonetheless varies across geographic regions and different ethnicities. In a report
on the incidence of hip fractures involving 33 countries or regions, the highest annual age-sex-
standardized hip fracture rates were found in Scandinavian countries (up to 47.74 per 10,000
population), compared with most European countries (up to 30.62 per 10,000 population) and
the US (up to 26.47 per 10,000 population). In Asia, the rate was higher in Hong Kong (23.58
per 10,000 population), Taiwan (26.99 per 10,000 population) and Singapore (24.21 per 10,000
population), than in Iran (9.58 per 10,000 population) and Mainland China (6.70–13.16 per
10,000 population). Furthermore, among men in the US, white men had a higher hip fracture
rate than Asians and blacks. [19] Differences in peak bone mass and skeletal geometry, genetic,
lifestyle and environmental factors are all possible explanations for these geographical varia-
tions.[19] [20] These racial differences were also evident among men receiving ADT. In a
study comparing the bone mineral density (BMD) and fracture incidence between African
American and Caucasian men prescribed ADT, Caucasian men tended to develop more frac-
tures during ADT. Since the decline in BMD was similar between the two groups, this might
be attributed to the higher baseline BMD in African Americans.[21] Nonetheless although lit-
erature is scarce, Caucasian men receiving ADT tended to have a higher incidence of osteopo-
rosis than Asians. In a study involving 58 Japanese men who received ADT, the incidence of
osteoporosis by BMD was 10.8%, lower than that reported in a Caucasian series.[22] In our
study, the incident fracture rate was 10.3% among men who received ADT, similar to the 9.8%
reported in a recent Taiwan study of 17359 men with carcinoma of the prostate.[23] This
again raises the possibility that geographical variations and racial differences might also play a
role in determining susceptibility to ADT-related bone loss and fracture incidence in men pre-
scribed ADT for carcinoma of the prostate.
There are at least four different types of ADT, each with its own strengths and limitations.
[16] Nonetheless, to date, there is a paucity of data directly comparing their associated fracture
risk. Bilateral orchiectomy and LHRHa are two common forms of ADT offered to patients
with metastatic carcinoma of the prostate or locally advanced disease. Either of them alone has
been shown to increase fracture risk in previous studies [12,13], but few have compared their
relative risks.[23] In a study involving more than 50,000 men with carcinoma of the prostate,
among those prescribed ADT, 19% suffered from a fracture. The relative risk was 1.54 (95% CI
1.42–1.68) for orchiectomy and 1.45 (95% CI 1.36–1.56) for those who received more than
nine doses of LHRHa. Nevertheless this study also included possible pathological fractures
resulting from bone metastases.[9] It was recently shown in a Chinese cohort of 17,359 patients
with carcinoma of the prostate in Taiwan that the rate of fracture-free survival was highest in
those without ADT, followed by those prescribed LHRHa, and lowest among those who had
bilateral orchiectomy ± LHRHa. Nonetheless, there was still no exact comparison of fracture
risk between these two common forms of ADT.[23]
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In our cohort, all forms of ADT, including bilateral orchiectomy ± anti-androgens, LHRHa ±
anti-androgens, and anti-androgens monotherapy were associated with a significant increase in
incident fracture. However, there was no significant difference in the relative risks among the three
modalities. In men, testosterone is the most important androgen and is closely related to bone
health, either directly affecting osteogenesis [24] or indirectly through aromatization to estradiol.
[25] To date, androgen deprivation can be achieved in several ways, acting at different levels of the
hypothalamic-pituitary-gonadal axis: Bilateral orchiectomy brings about a rapid, irreversible and
pronounced suppression of serum testosterone levels, LHRHa causes suppression of LH, FSH and
serum testosterone over time, and most anti-androgens compete with serum androgens at the
receptor level. Fig 2 depicts the association of different types of ADT with bone health. Our results
highlighted that androgen deprivation, irrespective of the mechanisms through which it is achieved,
produced deleterious effects on bone health. In a prospective study involving 618 men with carci-
noma of the prostate, the use of bicalutamide, a potent non-steroidal anti-androgen, was shown to
maintain BMD while LHRHa decreased BMD. The authors suggested that this was likely an effect
of increased estradiol levels produced from aromatization of the increased amount of serum testos-
terone available under androgen receptor blockade.[26] In our cohort, only 11% of subjects were
prescribed bicalutamide and a large majority of subjects were on flutamide as anti-androgen mono-
therapy. In contrast to bicalutamide with no effect on adrenal androgen, flutamide was shown to
significantly reduce the level of dehydroepiandrosterone (DHEA) in addition to androgen receptor
blockade.[27] However, whether reduction in adrenal androgen contributes to fracture risk in
patients with carcinoma of the prostate remains to be confirmed by further studies. (Fig 2)
In our study, diabetes mellitus was also associated with increased risk of fracture in patients
with carcinoma of the prostate. Type 2 diabetes mellitus has been linked with bone fragility via
multiple proposed mechanisms, including reduced insulin growth factor-1 (IGF1) production,
vitamin D deficiency and increased circulating advanced glycation end-products (AGE). In
addition, insulin resistance is associated with low testosterone levels that may further aggravate
bone fragility in men receiving ADT.[28]
Our findings certainly have important implications in the management of carcinoma of the
prostate. Several decades have passed since the discovery of ADT. Despite the increasingly rec-
ognized long term side effects of ADT, be it cardiovascular, metabolic or skeletal complica-
tions, there remains an important role of ADT in patients suffering from metastatic carcinoma
of the prostate and those with high-risk and locally advanced disease, in terms of both symp-
tom palliation and survival benefits.[29,30] Our study provides additional information about
the bone-related side effects of ADT, highlighting that although a form of ADT might be
Fig 2. Association of different types of androgen deprivation therapy with bone health.
doi:10.1371/journal.pone.0171495.g002
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chosen for their merits of reversibility (e.g. LHRHa), or rapid and pronounced testosterone
suppression (e.g. bilateral orchiectomy), or compliance (e.g. anti-androgen monotherapy),
their deleterious effects on bone health occurred at a similar extent, hence more comprehen-
sive counseling about the anticipated risks and related preventive measures could be afforded
to patients who are prescribed ADT. On the other hand, for patients with less advanced dis-
ease, understanding more about these fracture risks enables clinicians to derive a clearer risk-
benefit ratio while prescribing ADT for their patients, especially in the elderly population and
those with type 2 diabetes, who are already at a higher risk of incident fracture. This is particu-
larly important since patient’s quality of life can be significantly affected by the occurrence of
an ADT-related clinical fracture or cardiovascular disease.
Limitations
The study was limited by its single-centered observation design and the relatively small sample
size. Due to registry design, the selection of ADT was not in a randomized controlled fashion.
Patients who were prescribed ADT were in some way different to their counterparts who were
not treated with ADT as judged by their attending urologists. Thus selection bias was possible.
Importantly, given the nature of the study, we lacked the ability and access to have all other fac-
tors described, quantified and compared, including some important data such as bone mineral
density, alcohol consumption, socio-economic status, serum testosterone level that may influ-
ence the treatment choice as well as the nominal fracture risk. In addition, some newer agents
for ADT such as GnRH antagonists or abiraterone, were not available during the study period.
While we carefully ascertained all fracture events by detailed examination of hospital records,
laboratory and imaging results, we did not include patients with a milder form of fracture who
were not hospitalized.
Nonetheless, our study has compared the fracture risks of various types of ADT among Chi-
nese patients with carcinoma of the prostate. As all forms of ADT increase incident fracture
without demonstrable difference in relative risks among them, we highlight the need for pre-
ventive measures to optimize bone health before and during ADT, irrespective of the types of
ADT prescribed. These include adequate calcium and vitamin D intake and/or supplements,
as well as regular weight-bearing exercises. Current clinical practice guidelines recommend
BMD evaluation with dual energy X-ray absorptiometry in men aged 50 or above who were
hypogonadal or prescribed LHRHa.[31] Moreover, in men receiving ADT, measuring radius
BMD might be particularly helpful as BMD of the ultra distal radius was found to decline at a
greater extent than the spine and hip.[31,32] In those who are at high risk of fracture, pharma-
cological agents like bisphosphonate therapy, either oral or intravenous, or denosumab can be
considered [31], so that ADT will improve the overall survival of patients with prostate cancer
without compromising their quality of life.
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